iPSC for modeling neurodegenerative disorders

被引：22

作者：

Valadez-Barba, Valeria ^{[1
]}

Cota-Coronado, A. ^{[1
,2
]}

Hernandez-Perez, O. R. ^{[1
]}

Lugo-Fabres, Pavel H. ^{[1
]}

Padilla-Camberos, Eduardo ^{[1
]}

Fabian Diaz, Nestor ^{[3
]}

Emmanuel Diaz-Martinez, N. ^{[1
]}

机构：

[1] Ctr Res & Assistance Technol & Design State Jalis, Dept Med & Pharmaceut Biotechnol, Av Normalistas 800, Colinas De Las Normal 44270, Jalisco, Mexico

[2] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, 30 Royal Parade, Parkville, Vic 3052, Australia

[3] Inst Nacl Perinatol Isidro Espinosa Reyes, Dept Fisiol & Desarrollo Celular, Mexico City, DF, Mexico

来源：

REGENERATIVE THERAPY | 2020年 / 15卷

关键词：

iPSCs; Neurodegenerative diseasaes; Alzheimer; Parkinson; PLURIPOTENT STEM-CELLS; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; A-BETA; NEURONS; MOUSE; TRANSPLANTATION; SENSITIVITY; PATHOLOGY; THERAPY;

D O I：

10.1016/j.reth.2020.11.006

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Neurodegenerative disorders such as Parkinson's and Alzheimer's disease, are fundamental health concerns all around the world. The development of novel treatments and new techniques to address these disorders, are being actively studied by researchers and medical personnel. In the present review we will discuss the application of induced Pluripotent Stem Cells (iPSCs) for cell-therapy replacement and disease modelling. The aim of iPSCs is to restore the functionality of the damaged tissue by replacing the impaired cells with competitive ones. To achieve this objective, iPSCs can be properly differentiated into virtually any cell fate and can be strongly translated into human health via in vitro and in vivo disease modeling for the development of new therapies, the discovery of biomarkers for several disorders, the elaboration and testing of new drugs as novel treatments, and as a tool for personalized medicine. (C) 2020, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.

引用

页码：332 / 339

页数：8

共 78 条

[1]

Alexander Garrett E, 2004, Dialogues Clin Neurosci, V6, P259

[2]

BACH FH, 1968, LANCET, V2, P1364

[3] Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease [J].

Butterfield, D. Allan ;

Halliwell, Barry .

NATURE REVIEWS NEUROSCIENCE, 2019, 20 (03) :148-160

[4] Origin of the Induced Pluripotent Stem Cells Affects Their Differentiation into Dopaminergic Neurons [J].

Chlebanowska, Paula ;

Sulkowski, Maciej ;

Skrzypek, Klaudia ;

Tejchman, Anna ;

Muszynska, Agata ;

Noroozi, Rezvan ;

Majka, Marcin .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) :1-23

[5] Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson's Disease [J].

Cooper, Oliver .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (141)

[6] SENILE AMYLOIDOSIS - A PROTEAN MANIFESTATION OF THE AGING PROCESS [J].

CORNWELL, GG ;

WESTERMARK, P .

JOURNAL OF CLINICAL PATHOLOGY, 1980, 33 (12) :1146-1152

[7] Generation of human induced pluripotent stem cell line UNIGEi003-A from skin fibroblasts of an apparently healthy male donor [J].

Cosset, Erika ;

Vannary, Tieng ;

Sloan-Bena, Frederique ;

Gimelli, Stefania ;

Gerstel, Eric ;

Krause, Karl-Heinz ;

Marteyn, Antoine .

STEM CELL RESEARCH, 2020, 48

[8] The Cellular Phase of Alzheimer's Disease [J].

De Strooper, Bart ;

Karran, Eric .

CELL, 2016, 164 (04) :603-615

[9] Caloric restriction, metabolic rate, and entropy [J].

Demetrius, L .

JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2004, 59 (09) :902-915

[10] Alzheimer's as a metabolic disease [J].

Demetrius, Lloyd A. ;

Driver, Jane .

BIOGERONTOLOGY, 2013, 14 (06) :641-649

← 1 2 3 4 5 6 7 8 →